H.C. Wainwright raised the firm’s price target on Kezar Life Sciences to $20 from $18 and keeps a Buy rating on the shares. The Regional licensing deal extends the company’s operational runway and reduces clinical execution risk, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KZR:
- Kezar Life Sciences enters into collaboration pact with Everest Medicines
- Kezar Life Sciences downgraded to Equal Weight from Overweight at Wells Fargo
- Kezar Life Sciences price target lowered to $18 from $19 at H.C. Wainwright
- Kezar Life Sciences reports Q2 EPS (34c), consensus (32c)
- Kezar Life Sciences (KZR) Q2 Earnings Cheat Sheet
